NCT00162500撤回2 期
A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- Determine the safety and tolerability of vaccination comprising the ImMucin vaccine
研究概览
简要总结
Rationale:
ImMucin was shown to be able to induce a robust cellular immune response mediated via both CD4+ and CD8+ T lymphocytes and therefore, could potentially be more effective in the majority of the target population.
Purpose:
The purpose of this study is to evaluate the safety and initial efficacy of ImMucin, a novel peptide vaccine in metastatic tumors expressing the MUC-1 Tumor Associated Antigen (TAA).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients must have a histological or cytological diagnosis of metastatic disease expressing the MUC-
- •Patients must have metastatic disease and have failed at least one regimen of standard based chemotherapy for metastatic disease such as:
- •Renal Cell Carcinoma (RCC),
- •Transitional Cell Carcinoma (TCC),
- •Prostate,
- •Non-small cell lung,
- •Multiple myeloma and
- •Pancreatic.
- •Patients must be >18 years of age, consenting to participation in the study.
- •Patients must have at least one site of measurable tumor or measurable tumor marker.
排除标准
- •Patients receiving any immunosuppressive treatment that could negate development of an effective immune response to the vaccine.
- •Subjects with prior irradiation to a field that includes more than 25% of their lymph nodes and bone marrow likely to be immunosuppressed will be excluded. However, patients who had standard pelvic field radiation such as adjuvant therapy for rectal cancer are not excluded.
- •Pregnant and breast feeding women will be excluded. Premenopausal women who are not practicing or willing to practice adequate birth control methods for a period of 3 months after treatment will be excluded.
- •Patients with brain metastases.
- •Patients with active infection.
- •Patients with HIV hepatitis B surface antigen (HBS Ag) and hepatitis C virus (HCV) positive patients.
结局指标
主要结局
Determine the safety and tolerability of vaccination comprising the ImMucin vaccine
combined with Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), in patients
with multiple myeloma and other MUC-1 antigen-expressing metastatic carcinomas
次要结局
- Determine objective anti-tumor response in patients treated with this regimen;
- Determine immune response in patients treated with this regimen
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor MalignanciesMultiple MyelomaNCT01232712Vaxil Therapeutics Ltd.15
已完成
早期 1 期
Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast CancerBreast CancerNCT00640861Mayo Clinic45
已完成
1 期
Vaccine Therapy Plus QS21 in Treating Patients With Prostate CancerProstate CancerNCT00005632Memorial Sloan Kettering Cancer Center27
已完成
2 期
Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal AdenomaRisk for Colorectal CancerNCT00773097Robert Schoen46
Unknown
1 期
Safety Study of Human MUC-1 (Mucin-1) Adenoviral Vector Vaccine for Immunotherapy of Epithelial CancersEpithelial Cancers of the Lung, Breast, Ovary, Prostate and ColonNCT02140996Singapore Clinical Research Institute24